Tessera Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Tessera Therapeutics's estimated annual revenue is currently $70.4M per year.
- Tessera Therapeutics's estimated revenue per employee is $155,000
- Tessera Therapeutics's total funding is $431.8M.
- Tessera Therapeutics's current valuation is $1.7B. (April 2022)
Employee Data
- Tessera Therapeutics has 454 Employees.
- Tessera Therapeutics grew their employee count by 24% last year.
Tessera Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $4.2M | 27 | 35% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $1.4M | 9 | 29% | N/A | N/A |
#6 | $235M | 255 | -31% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.3M | 34 | 0% | N/A | N/A |
#10 | $1.9M | 12 | -8% | N/A | N/A |
What Is Tessera Therapeutics?
Our mission is to cure disease by writing the code of life
keywords:N/A$431.8M
Total Funding
454
Number of Employees
$70.4M
Revenue (est)
24%
Employee Growth %
$1.7B
Valuation
N/A
Accelerator
Tessera Therapeutics News
2022-04-17 - Tessera Therapeutics Raises Over $300M in Series C Financing
Tessera Therapeutics, a Somerville, MA-based biotechnology company, raised over $300M in Series C funding.
2022-04-17 - Tessera Therapeutics stacks up more than $300M in series C funds ...
Tessera Therapeutics, founded and created by life sciences VC staple Flagship Pioneering, is building a war chest with a fresh $300 million...
2022-04-17 - Tessera Therapeutics Announces Over $300M Series C Financing ...
Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $99.8M | 456 | 8% | N/A |
#2 | $81.6M | 459 | -11% | $502.5M |
#3 | $58.7M | 460 | N/A | N/A |
#4 | $155.3M | 471 | 0% | $402.8M |
#5 | $108.5M | 482 | 21% | N/A |